Pharmacokinetic analysis and simplified uptake measures for tumour lesion [
Activated T-cells
ImmunoPET
Pharmacokinetic modelling
[18F]F-AraG
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
28
03
2024
accepted:
26
09
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
8
10
2024
Statut:
aheadofprint
Résumé
The novel positron emission tomography (PET) imaging tracer, [ Ten patients with early-stage NSCLC and three patients with advanced NSCLC underwent a dynamic PET scan of minimal 60 min. Venous and/or arterial blood sampling was obtained at maximum seven time points. Tumour lesion time activity curves and metabolite-corrected input functions were analysed using single-tissue reversible (1T2k), two-tissue irreversible (2T3k) and two-tissue reversible (2T4k) plasma input models. Simplified uptake measures, such as standardised uptake value (SUV) and tumour-to-blood (TBR) or tumour-to-plasma ratio (TPR), were evaluated for different time intervals. Whole-blood and plasma radioactivity concentrations showed rapid clearance of [ Tumour lesion [
Identifiants
pubmed: 39377810
doi: 10.1007/s00259-024-06931-3
pii: 10.1007/s00259-024-06931-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Boehringer Ingelheim
ID : Boehringer Ingelheim
Informations de copyright
© 2024. The Author(s).
Références
Brahmer J, Rodriguez-Abreu D, Robinson A, Hui R, Csőszi T, Fülöp A, et al. LBA51 KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥ 50%. Ann Oncol. 2020;31:S1181–2.
doi: 10.1016/j.annonc.2020.08.2284
Paz-Ares LG, Ramalingam SS, Ciuleanu T-E, Lee J-S, Urban L, Caro RB, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial. J Thorac Oncol. 2022;17:289–308.
doi: 10.1016/j.jtho.2021.09.010
pubmed: 34648948
Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30:R921–5.
doi: 10.1016/j.cub.2020.06.081
pubmed: 32810447
pmcid: 8194051
Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell. 2017;170:927–38. e20.
doi: 10.1016/j.cell.2017.07.025
pubmed: 28841418
pmcid: 5589211
Slebe M, Pouw JE, Hashemi SM, Menke-van der Houven CW, Yaqub MM, Bahce I. Current state and upcoming opportunities for immunoPET biomarkers in lung cancer. Lung Cancer. 2022;169:84–93.
doi: 10.1016/j.lungcan.2022.05.017
pubmed: 35679715
Namavari M, Chang YF, Kusler B, Yaghoubi S, Mitchell BS, Gambhir SS. Synthesis of 2’-deoxy-2’-[18F]fluoro-9-beta-D-arabinofuranosylguanine: a novel agent for imaging T-cell activation with PET. Mol Imaging Biol. 2011;13:812–8. https://doi.org/10.1007/s11307-010-0414-x .
doi: 10.1007/s11307-010-0414-x
pubmed: 20838911
Levi J, Duan H, Yaghoubi S, Packiasamy J, Huynh L, Lam T, et al. Biodistribution of a mitochondrial metabolic Tracer, [(18)F]F-AraG, in healthy volunteers. Mol Imaging. 2022;2022:3667417. https://doi.org/10.1155/2022/3667417 .
doi: 10.1155/2022/3667417
pubmed: 36072652
pmcid: 9400547
Sanford M, Lyseng-Williamson KA, Nelarabine. Drugs. 2008;68(4).
Levi J, Lam T, Goth SR, Yaghoubi S, Bates J, Ren G, et al. Imaging of Activated T Cells as an early predictor of Immune response to Anti-PD-1 therapy. Cancer Res. 2019;79:3455–65. https://doi.org/10.1158/0008-5472.CAN-19-0267 .
doi: 10.1158/0008-5472.CAN-19-0267
pubmed: 31064845
pmcid: 6606349
Li F, Li C, Cai X, Xie Z, Zhou L, Cheng B et al. The association between CD8 + tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: a systematic review and meta-analysis. EClinicalMedicine. 2021;41.
Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metabolism. 2001;21:635–52.
doi: 10.1097/00004647-200106000-00002
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54.
doi: 10.1007/s00259-014-2961-x
pubmed: 25452219
Kaalep A, Sera T, Rijnsdorp S, Yaqub M, Talsma A, Lodge MA, Boellaard R. Feasibility of state of the art PET/CT systems performance harmonisation. Eur J Nucl Med Mol Imaging. 2018;45:1344–61.
doi: 10.1007/s00259-018-3977-4
pubmed: 29500480
pmcid: 5993859
Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE. Soc Nuclear Med; 2018.
Yaqub M, Boellaard R, Kropholler MA, Lammertsma AA. Optimization algorithms and weighting factors for analysis of dynamic PET studies. Phys Med Biol. 2006;51:4217.
doi: 10.1088/0031-9155/51/17/007
pubmed: 16912378
Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19:716–23.
doi: 10.1109/TAC.1974.1100705
Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D’Souza A, et al. A PET imaging strategy to visualize activated T cells in Acute Graft-versus-host Disease elicited by allogenic hematopoietic cell transplant. Cancer Res. 2017;77:2893–902. https://doi.org/10.1158/0008-5472.CAN-16-2953 .
doi: 10.1158/0008-5472.CAN-16-2953
pubmed: 28572504
pmcid: 5505323
Omidvari N, Levi J, Abdelhafez YG, Wang Y, Nardo L, Daly ME et al. Total-body dynamic imaging and kinetic modeling of [18F] F-AraG in healthy individuals and a non–small cell Lung Cancer patient undergoing Anti–PD-1 immunotherapy. J Nucl Med. 2024;65(9):1481-1488.
Rothenburger T, McLaughlin K-M, Herold T, Schneider C, Oellerich T, Rothweiler F, et al. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine. Commun Biology. 2020;3:324.
doi: 10.1038/s42003-020-1052-8
Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):S11–20. https://doi.org/10.2967/jnumed.108.057182 .
doi: 10.2967/jnumed.108.057182
Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metabolism. 1983;3:1–7.
doi: 10.1038/jcbfm.1983.1